. . . . . . . . . . . . "[Novartis's second-generation ALK inhibitor ceritinib has been approved by the FDA for patients with ALK-positive lung cancer who relapse after first-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2016-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2016-05-13T12:50:49+02:00"^^ . . . . . . . . . . . "v4.0.0.0" . "v4.0.0" .